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Objectives: To assess the treatment patterns and current disease severity of 
patients with PsO receiving their first biologic in 5EU, namely, UK, Germany (DE), 
France (FR), Italy (IT) and Spain (SP). MethOds: A multi-country multi-center 
medical chart-review study of PsO patients was conducted among dermatologists 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration (3-30 yrs) and patient-volume (incl.> 2PsO biologic patients/
month) and recruited from a large panel to be geographically representative in 
each country. Physicians abstracted charts of next five consecutive biologic patients 
within each center/practice. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease severity. Results from patients 
on first biologic treatment were analyzed. Results: In 4Q2012, 225 physicians 
abstracted 924 eligible PsO patient charts; 690 (75%) were on their first biologic 
(mean-age:46.9yrs, female:36%). Geographic distribution-UK:18%, DE:21%, FR:19%, 
IT:21%, SP:21%. Time-to-1st biologic from diagnosis (months)/time-on-current bio-
logic (months) varied- UK:140/17, DE:119/10, FR:138/15, IT:103/18, SP:127/17. Top-4 
first-line biologic treatments observed were etanercept, adalimumab, infliximab 
and ustekinumab. Treatment experience prior to first biologic varied dramati-
cally (not mutually exclusive): Immunomodulators-UK:92%,DE:51%,FR:68%,IT:73
%,SP:76%; phototherapy-UK:55%,DE:71%,FR:59%,IT:32%,SP:37%; topicals-UK:41%
,DE:69%,FR:46%,IT:43%,SP:39%; retinoids-UK:29%,DE:30%,FR:34%,IT:42%,SP:40%; 
fumerates-UK:13%,DE:69%,FR:0%,IT:1%,SP:0%; corticosteroids-UK:2%,DE:32%,
FR:10%,IT:14%,SP:10%; Average # of flares in the past yr were: UK-1.0,DE-1.3,FR-
1.1,IT-1.0,SP-1.6. Mean current PASI scores were: UK-8,DE-20,FR-12,IT-18,SP-11. 
Current disease severity per physician judgment was (remission/mild/moder-
ate/severe): UK-45%/25%/20%/10%, DE-26%/19%/21%/35%, FR-42%/34%/15%/9%, 
IT-39%/19%/31%/11%, SP-44%/29%/26%/2%. Mean number of treatments prior to 
first biologic varied by current disease severity (remission/mild/moderate/severe): 
UK-2.7/3.1/2.6/3.1, DE-3.0/3.7/2.7/4.1, FR-2.2/2.6/2.2/2.4, IT-2.2/2.2/2.3/2.1, SP:2.4/2.
2/2.3/2.3. cOnclusiOns: Among PsO patients receiving their first biologic, treat-
ment patterns and disease severity varied across 5EU, with patients in Germany 
disproportionately experiencing higher disease burden. Factors influencing the 
observed variations in care and optimal therapeutic approaches (including treat-
ment sequencing) aligned with clinical guidelines to decrease patient disease bur-
den warrants scrutiny.
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Objectives: In the Czech Republic there are three modern molecules available for 
the treatment of multiple myeloma: bortezomib, thalidomide and lenalidomide. 
In order to better understand this evolving specific market, analysis of consump-
tion trends has been conducted with emphasis on the molecules’ mutual influ-
ence. MethOds: Time-consumption curves of bortezomib, lenalidomide and 
thalidomide since 2009, based on the economic data of the General Health Insurance 
Company of the Czech Republic, were analyzed. While there was reimbursement for 
thalidomide in the first line treatment and bortezomib in the second line in 2009, 
we focused on and evaluated the impact of the launch of lenalidomide in 2009 (as 
a second line treatment). We also investigated the extension of reimbursement of 
bortezomib for the use in the first line in 2010. Results: The introduction of lena-
lidomide (2009) led to a rapid decline in thalidomide consumption within the next 
year, in contrast to bortezomib, the consumption of which appeared unaffected. 
Furthermore, also the consumption of thalidomide decreased profoundly following 
the extension of reimbursement conditions of bortezomib (2010). The overall relative 
reduction in thalidomide consumption observed within the two years between 2009 
and 2011 was 70%. cOnclusiOns: The presented retrospective analysis shows that 
the impact of myeloma treatment on payers’ financial budgets has increased nearly 
3-times in the last four years. The extension of reimbursement of bortezomib had a 
clear impact on the consumption of thalidomide, which was its supposed compara-
tor in the first line therapy. However, it appears that even though the introduction 
of lenalidomide did also significantly affect the consumption of thalidomid, it had 
no apparent impact on the use of bortezomib.
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Objectives: To determine the prescribing and cost of appetite suppressants in a 
defined private sector patient population, as well as the prescribing of other medi-
cines to the patient sample. MethOds: A retrospective drug utilisation study was 
conducted on a medical insurance claims database in South Africa for 2010 and 
2011. No clinical information was available in the database. Results: In 2010, 37 
patients (86.49% females) were prescribed 44 appetite suppressants at a total cost 
of R9813.39, of which 75.0% were for phentermine. The average age of patients 
was 40.95 (SD= 12.37) years. In 2011, 27 patients (77.78% females) received 42 pre-
scriptions for appetite suppressants at a total cost of R9967.73. The average age of 
patients was 40.04 years (SD= 10.41) (females: 37.95 (SD= 7.76) years; males 47.33 
(SD= 10.52) years). Most products (80.95%) were for phentermine, followed by d-norp-
seudoephedrine (14.29%) and diethylpropion (4.76). Prescribing patterns in 2010 
and 2011 were similar. Appetite suppressants are strictly regulated in South Africa. 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Descriptive statistics are reported. Results: A total of 173 rheuma-
tologists participated in the survey. Years of experience practicing rheumatology 
was: < = 1yr:0%, 2-5yrs:6%, 6-10yrs:17%, 11-20yrs:42%, > 20yrs:32%. Geographic dis-
tribution of rheumatologists was: 5EU-58%, Brazil-23%, Japan-11% and China-9%. 
Mean RA patient-volume/year was 291 (5EU-329, Brazil-259, Japan-232 and China-
189). Overall, 47% of rheumatologists reported that they would prescribe a biosimi-
lar to their eligible RA patients “definitely or highly likely” (5EU:58%, Brazil:21%, 
Japan:47%, China:47%); 51% of rheumatologists reported that they would try using 
biosimilars for 1-2 yrs among a small group of patients in their practice before 
starting to use it in a majority of biologic-eligible RA patients in their practice 
(5EU:60%, Brazil:33%, Japan:42%, China:47%). The top-5 factors that would prevent 
them from using biosimilars were diverse across the countries (Overall/5EU/Brazil/
Japan/China): Doubts in similarity to original molecule 60%/63%/67%/47%/33%), 
inadequate safety/efficacy profile/data (53%/51%/51%/58%/60%), lack of long-term 
data (46%/51%/41%/32%/40%), lack of national guidelines recommending the use 
of biosimilars (37%/39%/31%/32%/47%) and lack of data from local country/market 
(31%/23%/41%/42%/47%). cOnclusiOns: Across markets, over half of the rheu-
matologists expressed concerns/reservations towards prescribing biosimilars to 
their eligible RA patients. While payer organizations look to biosimilars to contain 
costs and make medicines more affordable to RA patients in need, potential bar-
riers to biosimilar adoption may exist.
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Objectives: Biologic therapy is increasingly used to treat autoimmune dis-
orders in developed markets, but usage is still low in emerging markets. This 
analysis was conducted to identify factors associated with current use of bio-
logic medication among patients with autoimmune disorders in emerging mar-
kets. MethOds: Data were from the Brazil, China, and Russia National Health 
and Wellness Surveys, cross-sectional surveys representative of the total adult 
population (Brazil) or urban adult population (China and Russia) in each country, 
conducted in 2011 and 2012. Respondents self-reporting physician diagnosis of 
ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid 
arthritis, or ulcerative colitis and using a prescription medication (Rx) for at least 
one of those conditions were included; patients with missing data for any covari-
ate were excluded. Binomial logistic regression included the following predictors: 
age, sex, country, income, Charlson Comorbidity Index (CCI), body mass index 
(BMI), monthly out of pocket (OOP) costs for Rxs, fear of needles, condition severity, 
length of diagnosis, and type of treating physician. Results: Of 1,507 respondents 
included in the analysis, 300 (19.9%) were using a biologic. Of those, 82.0% (n= 246) 
were in China. Relative to China, patients were less likely to use biologics in Brazil 
(OR 0.21; 95% CI: 0.13, 0.36) and Russia (OR: 0.29, 95% CI: 0.18, 0.46; ps< 0.001). Higher 
CCI was associated with use of biologics (OR: 1.18, 95% CI: 1.10, 1.26; p< 0.001), 
as were higher OOP costs (OR: 2.37, 95% CI: 1.04, 5.42; p< 0.05) compared to no 
OOP costs. Fear of needles was positively associated with biologic use (OR: 1.57, 
95% CI: 1.18, 2.09; p< 0.01). No other covariates were significant. cOnclusiOns: 
Country was by the strongest predictor of biologic use in patients with autoim-
mune conditions in emerging markets, but higher costs and more comorbidities 
were associated with biologic use across emerging markets.
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Objectives: To compare the disease status, treatments and outcomes of patients 
with AS receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) 
with the US. MethOds: A multi-country multi-center medical chart-review study 
of AS patients was conducted between October-December 2012 among physicians 
(rheumatologists: 5EU: 97%, US: 99%) in hospitals and private practices to collect 
de-identified data on AS patients who were recently treated with a biologic as 
part of usual care. Physicians were screened for duration of practice and patient 
volume and recruited from a large panel to be geographically representative in 
each country. Eligible AS patient charts (> 2) were randomly selected from a sample 
of prospective patients visiting each center/practice during the screening period. 
Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status/outcomes. Results: Seven hundred and ninety 
seven eligible AS patient charts (5EU:613, US: 184) were abstracted; 701 (5EU:549, 
US: 152) patients were on their first biologic (mean-age: 5EU:42.5yrs/US:42.4yrs; 
female: 5EU:16.2%/US:17.1%). Time-to-1st biologic from diagnosis (5EU:55.3months/
US:46.8months) and time-on-current biologic (5EU:31.7months/US:44.3months) 
differed between regions. Top-2 biologic treatments observed were – adalimumab 
(5EU:43%/US:35%) and etanercept (5EU:30%/US:41%). Among the top-3 reasons for 
biologic treatment initiation, ‘mechanism of action’ & ‘improve signs/symptoms’ 
were observed in both 5EU and US, whereas ‘positive personal experience’ (5EU) and 
‘prevention of structural damage’ (US) were also observed. Key lab measures docu-
mented were: ESR (5EU:17.4mm/h, US:20.9mm/h) and CRP (5EU:8.8mg/dl, US:2.7mg/
dl). Current disease severity per physician-judgment (mild:moderate:severe) was: 
5EU-63%:32%:6%, US-62%:34%:5%. Among patients with available data, current HAQ 
(5EU:1.3, US:0.8), BASDAI (5EU:2.9, US:3.4), VAS provider score (5EU:2.9, US:2.5), VAS 
patient score (5EU:3.0, US:2.7), Swollen Joint Count (5EU:1.3, US:0.5), and Tender Joint 
Count (5EU:2.0, US:0.9) differed across regions. cOnclusiOns: Among AS patients 
receiving their first biologic, disease severity differed between 5EU and US, with 
patients in 5EU with relatively higher burden and poorer outcomes.
